SVB Leerink Maintains Market Perform on Amedisys, Lowers Price Target to $117
SVB Leerink analyst Whit Mayo maintains Amedisys (NASDAQ:AMED) with a Market Perform and lowers the price target from $131 to $117.
Raymond James Maintains Outperform on Amedisys, Lowers Price Target to $180
Raymond James analyst John Ransom maintains Amedisys (NASDAQ:AMED) with a Outperform and lowers the price target from $200 to $180.
Earnings Scheduled For April 27, 2022
Companies Reporting Before The Bell
• Deutsche Bank (NYSE:DB) is projected to report earnings for its first quarter.
UBS Upgrades Amedisys to Neutral, Raises Price Target to $168
UBS analyst Andrew Mok upgrades Amedisys (NASDAQ:AMED) from Sell to Neutral and raises the price target from $152 to $168.
Where Amedisys Stands With Analysts
Analysts have provided the following ratings for Amedisys (NASDAQ:AMED) within the last quarter:
Credit Suisse Maintains Outperform on Amedisys, Lowers Price Target to $195
Credit Suisse analyst A.J. Rice maintains Amedisys (NASDAQ:AMED) with a Outperform and lowers the price target from $200 to $195.
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell
• Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter.
SVB Leerink Maintains Market Perform on Amedisys, Raises Price Target to $147
SVB Leerink analyst Whit Mayo maintains Amedisys (NASDAQ:AMED) with a Market Perform and raises the price target from $145 to $147.